We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Device Enables Early Detection of Cancerous Skin Tumors

By LabMedica International staff writers
Posted on 29 Dec 2009
Israeli researchers are developing a new device that detects cancerous skin tumors, including melanomas that are not visible to the naked eye.

During initial testing by scientist from Ben-Gurion University of the Negev (Be'er Sheva, Israel), the optical spectro-polarimetric imaging (OSPI) instrument revealed new textures of lesions that have never been seen before--including melanoma in patients who were diagnosed with various skin lesions and were awaiting surgery for their removal. More...
The instrument diagnosed 73 types of lesions, some of them cancerous.

Dermatologists and plastic surgeons typically diagnose skin tumors by their appearance with the naked eye and only rarely using a dermatoscope--a magnifying tool that allows tumors to be examined in detail. The OSPI biosensor utilizes safe, infrared wavelengths and LC devices to measure tumor characteristics, including contours and spread.

"This is an exciting preliminary development since the initial testing shows that we can now identify microscopic tumors in the biological layers of the skin,” explained Prof. Abdulahim, who is head of the BGU Electro-Optical Unit in the faculty of engineering sciences and is leading the research group. "As we continue to develop the OSPI, we also see an opportunity to use this technology for detecting other types of cancerous growths.”

Cancerous mole detection is typically performed by looking for one or more characteristic visible symptoms: if the mole is asymmetrical; if its outline is blurred or irregular; if it has multiple colors; if it is larger than 5 mm in diameter; and if stands up above the skin.

According to the American Cancer Society (Atlanta, GA, USA), more than one million cases of skin cancer are diagnosed yearly in the United States. Melanoma, the most serious type of skin cancer, will account for approximately 8,650 of the 11,590 deaths due to skin cancer in 2009.

Israel has also seen a rise in skin cancer cases in recent years. According to the Health Ministry, 1 of every 39 men and 1 of every 50 women in Israel will be affected with melanoma in their lifetime.

Related Links:
Ben-Gurion University of the Negev


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Pipette Calibration System
Artel PCS®
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.